This is an international site for FEMARA^® (letrozole) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

Welcome to the Femara Product Website

FEMARA is approved for use in 104 countries around the world.

FEMARA Country-Level Websites

Below is a list of the countries that host a FEMARA website based on local label and in local language. They are intended for Health Care Professionals (HCPs) only. If you are a HCP from one of the countries listed below, click on your country link to be redirected to your country Femara website.

FEMARA International Website

This website is intended for Health Care Professionals (HCPs) outside the U.S. The information on this website is not country specific and may contain information that is outside the approved indication in the country in which you are located. Please contact your local representative for local prescribing information via www.novartisoncology.com/contactus.

IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EUSmPC)

Home
About FEMARA^®
Mechanism of Action Video

How does FEMARA^® work?

FEMARA^® works by reducing the production of estrogen wherever it is present in the body¹

FEMARA^® (letrozole) is a nonsteroidal aromatase inhibitor. It inhibits the aromatase enzyme by competitively binding to the haem of the cytochrome P450 subunit of the enzyme, resulting in a reduction of estrogen biosynthesis in all tissues.¹

FEMARA^® achieves its pharmacologic goals with a single once-daily tablet.¹ To learn more about FEMARA^® dosing convenience, see Dosage and Administration.

For information on the unique efficacy profile of FEMARA^®, click here.

Click here for Important Safety Information for FEMARA^®.

Reference: 1. FEMARA^® (letrozole) [summary of product characteristics]. Basel, Switzerland: Novartis Pharma AG; 2009.

Disclaimer: This is an international website for Femara^® (letrozole) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.